Q4 EPS Estimates for Sanara MedTech Reduced by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at HC Wainwright cut their Q4 2026 EPS estimates for shares of Sanara MedTech in a note issued to investors on Thursday, April 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.12 for the quarter, down from their prior forecast of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Several other brokerages have also issued reports on SMTI. Zacks Research lowered Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Wall Street Zen raised shares of Sanara MedTech from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $36.00.

Sanara MedTech Stock Performance

Shares of SMTI stock opened at $17.24 on Friday. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95. The stock’s 50-day moving average is $19.49 and its two-hundred day moving average is $23.84. The company has a debt-to-equity ratio of 7.75, a current ratio of 1.80 and a quick ratio of 1.59. The firm has a market cap of $158.09 million, a P/E ratio of -4.08 and a beta of 1.10.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). The company had revenue of $27.55 million during the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Sanara MedTech by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after acquiring an additional 6,049 shares in the last quarter. Stonebridge Wealth Management LLC boosted its position in Sanara MedTech by 17.8% during the fourth quarter. Stonebridge Wealth Management LLC now owns 134,934 shares of the company’s stock worth $3,151,000 after purchasing an additional 20,353 shares during the period. Royal Bank of Canada grew its holdings in Sanara MedTech by 127.3% during the fourth quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after purchasing an additional 65,887 shares during the last quarter. Geode Capital Management LLC grew its holdings in Sanara MedTech by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock valued at $1,846,000 after purchasing an additional 546 shares during the last quarter. Finally, Marshall Wace LLP raised its position in shares of Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after purchasing an additional 42,237 shares during the period. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.